250,000 UK NHS patients gain access to weight loss drug Mounjaro beyond diabetes treatment.

Mounjaro (tirzepatide), a weight loss drug, will soon be available to nearly 250,000 NHS patients in the UK, expanding access beyond diabetes treatment. It mimics hormones that signal fullness, proving more effective than semaglutide for weight loss. However, it will be prescribed alongside specialist weight loss services, and there are concerns about potential supply issues and increased demand affecting access for diabetes patients.